Pfizer to Canada Americans Cross Border for $35 Insulin | Robert Reich

 

What happens when life-saving medication costs $300 in America but $35 across the border in Canada? 

In this analysis, Robert Reich reveals the devastating story behind pharmaceutical companies relocating to Canada while Americans die from rationing insulin they can't afford. While Trump eliminated price controls and attacked Canada's healthcare system as "unfair competition," Mark Carney quietly offered Pfizer, Moderna, and AstraZeneca something America refused to provide: regulatory stability, coordinated approval with Europe, and a framework where medications are priced to save lives rather than maximize profits. This isn't just about one drug or one disease; it's about an entire industry choosing stability over exploitation. For Sarah, a Cleveland teacher driving six hours to Windsor every month to buy affordable insulin, this means choosing between medication and rent. For Montreal biotech researchers earning over $100,000 developing breakthrough cancer treatments, this means working where their innovations will actually reach patients. Because when pharmaceutical companies discover they can operate profitably in regulated systems, they stop defending predatory American pricing and relocate to countries that won't allow patients to die for corporate profits. 

 

 

 Source: Reich Analytics